Dynamic ASPECTS of Internal PRE-ACTIVATION of Effects Sensors of Voluntary ACTION in PARKINSON's Disease

Parkinson's Disease Clinical Trial

— DYNIDEO  

Official title:

The Impact of Parkinson's Disease on Internal Preactivation of Sensory Effects of Intention-based Actions. A Subliminal Priming Study

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT02894320
• Other study ID #: JBL_2014-28
• Status: Completed
• Start date: March 2015
• Est. completion date: September 2017

Study information

• Verified date: August 2018
• Source: Fondation Ophtalmologique Adolphe de Rothschild
• Contact: n/a
• Is FDA regulated: No
• Study type: Observational

Clinical Trial Summary

The ability to predict sensory effects of people's own motor actions is a key component of Human action realization. Recent studies revealed this anticipation process to be involved in early and late stages of voluntary actions. Nevertheless, the question whether the action-effect anticipation is impacted or not by "motor pathologies", such as the Parkinson's disease, remains unclear. The current study is aimed to clarify this issue by using a subliminal priming paradigm in patients with Parkinson's disease and in matched control participants. Indeed, subliminal primes corresponding to visual action-effects are displayed at different time points before the actions' execution. Results should allow to determine whether or not the action-effect prediction is impaired at different stages of voluntary action in patients with Parkinson's disease.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 28
• Est. completion date: September 2017
• Est. primary completion date: June 2016
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

• Adults age 18 years and older

• Parkinson's disease

Exclusion Criteria:

• Other pathology or neurological or psychiatric history

• Known pregnancy or breastfeeding

• Absence of affiliation to social security or universal health coverage (CMU)

• Person under legal protection

• Patient's opposition to participate

Related Conditions & MeSH terms

• Parkinson Disease
• Parkinson's Disease

Intervention

Behavioral:
• Behavioral observation

Locations

Country	Name	City	State
France	Fondation Ophtalmologique Adolphe de Rothschild	Paris

Sponsors (1)

Lead Sponsor	Collaborator
Fondation Ophtalmologique Adolphe de Rothschild

Country where clinical trial is conducted

France, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Reaction time	time measured in seconds	baseline
Primary	error rate		baseline